KOD Jason Ehrlich sells $338K worth of shares
Jan 04, 2026, 5:44 AM
0.00%
What does KOD do
Kodiak Sciences, a clinical-stage biopharmaceutical company based in Palo Alto, develops therapeutics for retinal diseases, including tarcocimab and KSI-501, using its innovative ABC Platform. The company went public on October 4, 2018, and employs 107 staff.
Jason Ehrlich sold 6,950 shares of KOD on 20 March at $48.59 per share, worth a total of $338K. They now own 29,259 KOD shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.